Pertagen Dosage/Direction for Use

Posology: A single 0.5 mL dose of Pertagen is recommended.
Pertagen may be given in individuals aged 3 years and onwards requiring protection against pertussis only as booster, catch-up or maternal immunization in accordance with national, WHO, US or EU official recommendations or medical practices, including: pregnant women in the second or third trimester and preferably at least 15 days before the end of pregnancy to prevent pertussis in mothers and in infants too young to be vaccinated; multiparous women with closely spaced pregnancies to avoid "over-vaccination" and hypersensitivity reactions due to repeated injections of Tdap-IPV or Tdap vaccines; adolescents, adults, household contacts, childcare providers to maintain herd immunity and to protect the youngest infants; healthcare providers to prevent nosocomial transmission to infants.
Pertagen may be considered as an alternative to acellular pertussis combinations (DTaP or Tdap-based vaccines) for pertussis booster immunization in subjects with known hypersensitivity to tetanus (Arthus-type hypersensitivity reaction) or diphtheria vaccines and in individuals who have received multiple and frequent tetanus or diphtheria vaccine doses.
Administration: Pertagen should be administered by deep intramuscular injection, preferably in the deltoid region. The skin over the site of injection should be cleaned before injection. Shake well before use. Do not use if resuspension does not occur after vigorous-shaking. Open the needle cap of the pre-filled syringe, administer the total volume of 0.5 mL intramuscularly (IM).